Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

References

• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Lizee G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annu Rev Med 2013; 64:71-90; PMID:23092383; http://dx.doi.org/10.1146/annurev-med-112311-083918
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Pitt JM, Charrier M, Viaud S, Andre F, Besse B, Chaput N, Zitvogel L. Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J Immunol 2014; 193:1006-11; PMID:25049431; http://dx.doi.org/10.4049/jimmunol.1400703
   PubMed Web of Science ®Google Scholar
• Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol 2014; 14:195-208; PMID:24566916; http://dx.doi.org/10.1038/nri3622
   PubMed Web of Science ®Google Scholar
• Viaud S, Terme M, Flament C, Taieb J, Andre F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PloS One 2009; 4:e4942; PMID:19319200; http://dx.doi.org/10.1371/journal.pone.0004942
   PubMed Web of Science ®Google Scholar
• Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, Le Pecq JB. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002; 270:211-26; PMID:12379326; http://dx.doi.org/10.1016/S0022-1759(02)00330-7
   PubMed Web of Science ®Google Scholar
• Viaud S, Thery C, Ploix S, Tursz T, Lapierre V, Lantz O, Zitvogel L, Chaput N. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res 2010; 70:1281-5; PMID:20145139; http://dx.doi.org/10.1158/0008-5472.CAN-09-3276
   PubMed Web of Science ®Google Scholar
• Escudier B, Dorval T, Chaput N, Andre F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Trans Med 2005; 3:10; PMID:15740633; http://dx.doi.org/10.1186/1479-5876-3-10
   PubMed Web of Science ®Google Scholar
• Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Trans Med 2005; 3:9; PMID:15723705; http://dx.doi.org/10.1186/1479-5876-3-9
   PubMed Web of Science ®Google Scholar
• Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26:3552-9; PMID:18506026; http://dx.doi.org/10.1200/JCO.2007.13.9030
   PubMed Web of Science ®Google Scholar
• Polo V, Besse B. Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs? Ann Oncol 2014; 25:1283-93; PMID:24351398; http://dx.doi.org/10.1093/annonc/mdt529
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30:2046-54; PMID:22547592; http://dx.doi.org/10.1200/JCO.2011.38.4032
   PubMed Web of Science ®Google Scholar
• Segura E, Nicco C, Lombard B, Veron P, Raposo G, Batteux F, Amigorena S, Thery C. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 2005; 106:216-23; PMID:15790784; http://dx.doi.org/10.1182/blood-2005-01-0220
   PubMed Web of Science ®Google Scholar
• Utsugi-Kobukai S, Fujimaki H, Hotta C, Nakazawa M, Minami M. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol Lett 2003; 89:125-31; PMID:14556969; http://dx.doi.org/10.1016/S0165-2478(03)00128-7
   PubMed Web of Science ®Google Scholar
• Viaud S, Ploix S, Lapierre V, Thery C, Commere PH, Tramalloni D, Gorrichon K, Virault-Rocroy P, Tursz T, Lantz O et al. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-gamma. J Immunother 2011; 34:65-75; PMID:21150714; http://dx.doi.org/10.1097/CJI.0b013e3181fe535b
   PubMed Web of Science ®Google Scholar
• Segura E, Amigorena S, Thery C. Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells, Mol Dis 2005; 35:89-93; PMID:15990342; http://dx.doi.org/10.1016/j.bcmd.2005.05.003
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Gettinger SN, Das R, Zebroski H, Dhodapkar MV. SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer. Oncoimmunology 2013; 2:e25205; PMID:24073380; http://dx.doi.org/10.4161/onci.25205
   PubMedGoogle Scholar
• Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994; 265:106-9; PMID:8016643; http://dx.doi.org/10.1126/science.8016643
   PubMed Web of Science ®Google Scholar
• Kamper N, Franken S, Temme S, Koch S, Bieber T, Koch N. Gamma-Interferon-regulated chaperone governs human lymphocyte antigen class II expression. FASEB J: Off Pub Federat Am Soc Exp Biol 2012; 26:104-16; PMID:21940994; http://dx.doi.org/10.1096/fj.11-189670
   PubMed Web of Science ®Google Scholar
• Pai RK, Askew D, Boom WH, Harding CV. Regulation of class II MHC expression in APCs: roles of types I, III, and IV class II transactivator. J Immunol 2002; 169:1326-33; PMID:12133955; http://dx.doi.org/10.4049/jimmunol.169.3.1326
   PubMed Web of Science ®Google Scholar
• Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Boll B, Simhadri VL, Borchmann P et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007; 27:965-74; PMID:18055229; http://dx.doi.org/10.1016/j.immuni.2007.10.010
   PubMed Web of Science ®Google Scholar
• Matta J, Baratin M, Chiche L, Forel JM, Cognet C, Thomas G, Farnarier C, Piperoglou C, Papazian L, Chaussabel D et al. Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood; 2013; 122:394-404; PMID:23687088; http://dx.doi.org/10.1182/blood-2013-01-481705
   PubMed Web of Science ®Google Scholar
• Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot DP, Vely F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med 2015; 7:283ra55; PMID:25877893; http://dx.doi.org/10.1126/scitranslmed.aaa2327; in press
   PubMed Web of Science ®Google Scholar
• Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, Andre P, Dieu-Nosjean MC, Alifano M, Regnard JF et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011; 71:5412-22; PMID:21708957; http://dx.doi.org/10.1158/0008-5472.CAN-10-4179
   PubMed Web of Science ®Google Scholar
• Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes RM, Busund LT. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology 2009; 55:301-12; PMID:19723145; http://dx.doi.org/10.1111/j.1365-2559.2009.03379.x
   PubMed Web of Science ®Google Scholar
• Takanami I, Takeuchi K, Giga M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Sur 2001; 121:1058-63; PMID:11385371; http://dx.doi.org/10.1067/mtc.2001.113026
   PubMed Web of Science ®Google Scholar
• Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, Hucke C, Kohl U, Durkop H, Engert A et al. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther: J Am Soc Gene Ther 2013; 21:895-903; PMID:23459515; http://dx.doi.org/10.1038/mt.2013.14
   PubMed Web of Science ®Google Scholar
• Reiners KS, Topolar D, Henke A, Simhadri VR, Kessler J, Sauer M, Bessler M, Hansen HP, Tawadros S, Herling M et al. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood 2013; 121:3658-65; PMID:23509156; http://dx.doi.org/10.1182/blood-2013-01-476606
   PubMed Web of Science ®Google Scholar
• Binici J, Koch J. BAG-6, a jack of all trades in health and disease. Cell Mol Life Sci: CMLS 2014; 71:1829-37; PMID:24305946; http://dx.doi.org/10.1007/s00018-013-1522-y
   PubMed Web of Science ®Google Scholar
• Corduan A, Lecomte S, Martin C, Michel D, Desmots F. Sequential interplay between BAG6 and HSP70 upon heat shock. Cell Mol Life Sci: CMLS 2009; 66:1998-2004; PMID:19357808; http://dx.doi.org/10.1007/s00018-009-9198-z
   PubMed Web of Science ®Google Scholar
• Thress K, Song J, Morimoto RI, Kornbluth S. Reversible inhibition of Hsp70 chaperone function by Scythe and Reaper. EMBO J 2001; 20:1033-41; PMID:11230127; http://dx.doi.org/10.1093/emboj/20.5.1033
   PubMed Web of Science ®Google Scholar
• Massa C, Melani C, Colombo MP. Chaperon and adjuvant activity of hsp70: different natural killer requirement for cross-priming of chaperoned and bystander antigens. Cancer Res 2005; 65:7942-9; PMID:16140966; http://dx.doi.org/10.1158/0008-5472.CAN-05-0377
   PubMed Web of Science ®Google Scholar
• Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, Multhoff G. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res 2005; 65:5238-47; PMID:15958569; http://dx.doi.org/10.1158/0008-5472.CAN-04-3804
   PubMed Web of Science ®Google Scholar
• Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, Kufer TA, Engert A, Pogge von Strandmann E. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PloS One 2008; 3:e3377; PMID:18852879; http://dx.doi.org/10.1371/journal.pone.0003377
   PubMed Web of Science ®Google Scholar
• Gross C, Schmidt-Wolf IG, Nagaraj S, Gastpar R, Ellwart J, Kunz-Schughart LA, Multhoff G. Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells. Cell Stress Chaperon 2003; 8:348-60; PMID:15115287; http://dx.doi.org/10.1379/1466-1268(2003)008%3c0348:HSPRIA%3e2.0.CO;2
   PubMed Web of Science ®Google Scholar
• Gross C, Hansch D, Gastpar R, Multhoff G. Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. Biol Chem 2003; 384:267-79; PMID:12675520; http://dx.doi.org/10.1515/BC.2003.030
   PubMed Web of Science ®Google Scholar
• Germain RN, Bajenoff M, Castellino F, Chieppa M, Egen JG, Huang AY, Ishii M, Koo LY, Qi H. Making friends in out-of-the-way places: how cells of the immune system get together and how they conduct their business as revealed by intravital imaging. Immunol Rev 2008; 221:163-81; PMID:18275481; http://dx.doi.org/10.1111/j.1600-065X.2008.00591.x
   PubMed Web of Science ®Google Scholar
• Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17:700-7; PMID:21552268; http://dx.doi.org/10.1038/nm.2366
   PubMed Web of Science ®Google Scholar
• Zornig I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N et al. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients. Int J Cancer 2015; 136:138-51; PMID:24839182; http://dx.doi.org/10.1002/ijc.28980
   PubMed Web of Science ®Google Scholar
• Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D, Jagannath S, Zebroski HA, Simpson AJ, Ritter G et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 2007; 204:831-40; PMID:17389240; http://dx.doi.org/10.1084/jem.20062387
   PubMed Web of Science ®Google Scholar